Occurrence of acute myeloid leukemia in hydroxyurea-treated sickle cell disease patient.
- Resource Type
- Report
- Authors
- Regan, Samuel; Yang, Xuebin; Finnberg, Niklas K.; El-Deiry, Wafik S.; Pu, Jeffrey J.
- Source
- Cancer Biology & Therapy. 2019, Vol. 20 Issue 11, p1389-1397. 9p.
- Subject
- *ACUTE myeloid leukemia
*SICKLE cell anemia
*P53 antioncogene
*MOLECULAR genetics
*SOMATIC mutation
*SICKLE cell trait
- Language
- ISSN
- 1538-4047
Hydroxyurea (HU) has been widely used in sickle cell disease. Its potential long-term risk for carcinogenesis or leukemogenic risk remains undefined. Here, we report a 26 y old African-American female with Sickle Cell Disease (SCD) who developed refractory/relapsed acute myeloid leukemia (AML) 6 months after 26 months of HU use. That patient's cytogenetics and molecular genetics analyses demonstrated a complex mutation profile with 5q deletion, trisomy 8, and P53 deletion (deletion of 17p13.1). P53 gene sequence studies revealed a multitude of somatic mutations that most suggest a treatment-related etiology. The above-mentioned data indicates that the patient may have developed acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) as a direct result of HU exposure. [ABSTRACT FROM AUTHOR]